Every 10-Q that Assertio Holdings, Inc. (ASRT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASRT filings page.
Assertio Holdings reported a weak first quarter while setting up a major strategic exit. Revenue fell to $9.9 million from $26.5 million a year earlier, driven by a sharp drop in ROLVEDON and INDOCIN sales. Net loss widened to $18.9 million, or $2.93 per share, from $13.5 million.
Cash and cash equivalents rose to $33.7 million, with short‑term investments of $37.9 million, giving sizable liquidity against $40.0 million of 6.5% Convertible Senior Notes due 2027. After quarter‑end, Assertio agreed to be acquired by Garda Therapeutics for $21.80 per share in cash via tender offer and merger, and sold all non‑ROLVEDON assets to Cosette for $35.0 million plus potential milestones, leaving ROLVEDON as its only product going forward.
Assertio Holdings (ASRT) reported stronger Q3 2025 results, with total revenue of $49.5 million, up from $29.2 million a year ago, and net income of $11.4 million versus a prior-year loss. Diluted EPS was $0.11. Growth was led by ROLVEDON product sales of $38.6 million in the quarter.
Management noted that Q3 included large distributor purchases of ROLVEDON to support integration into Assertio Specialty, accompanied by higher discounts and extended payment terms. The company anticipates no material net product sales of ROLVEDON in Q4 2025 and Q1 2026, with regular sales of newly labeled product expected to begin in Q2 2026.
For the nine months, revenue was $105.2 million and net loss was $18.4 million, reflecting an $8.2 million loss on the Assertio Therapeutics divestiture and portfolio actions. Cash and cash equivalents were $38.5 million and short-term investments were $54.9 million as of September 30, 2025; accounts receivable rose to $141.3 million and accrued rebates/returns/discounts to $130.5 million tied to Q3 sales terms. The company recorded a $1.7 million SPRIX intangible impairment and revised SPRIX’s remaining life to one year. Long-term debt consisted of $40.0 million principal of 6.5% convertible notes due 2027. Shares outstanding were 96,252,087 as of November 6, 2025.
Assertio Holdings (ASRT) reported lower revenue and wider losses for the quarter and first half of 2025 while taking strategic steps to simplify the business. Total revenues were $29.2 million for the three months and $55.7 million for the six months ended June 30, 2025, down from $31.1 million and $63.6 million a year earlier, respectively, driven by lower INDOCIN sales despite higher ROLVEDON sales of $16.1 million in the quarter. Cost pressures included higher amortization of intangibles of $9.2 million in the quarter.
The company recorded a net loss of $16.4 million ($0.17 per share) for the quarter and $29.9 million ($0.31 per share) for the six months, which includes an $8.2 million loss on the divestiture of Assertio Therapeutics. Total assets declined to $273.8 million and shareholders' equity fell to $93.3 million. Cash and cash equivalents were $47.1 million with short-term investments of $51.1 million.
Material operational items: the Therapeutics divestiture removed Assertio from opioid-related litigation exposure but produced an $8.2 million loss; the company ceased commercialization of Otrexup (incurring $3.8 million of related costs); management recorded a $16.0 million accrual related to the Luo settlement with corresponding insurance recoverable that was later settled and reduced to zero. The company maintains $39.0 million of 6.5% convertible notes due 2027 and a full valuation allowance on deferred tax assets.